Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction

被引:65
作者
Nikolsky, E
Sadeghi, HM
Effron, MB
Mehran, R
Lansky, AJ
Na, YB
Cox, DA
Garcia, E
Tcheng, JE
Griffin, JJ
Stuckey, TD
Turco, M
Carroll, JD
Grines, CL
Stone, GW [1 ]
机构
[1] Columbia Univ, Med Ctr, New York, NY 10027 USA
[2] Cardiovasc Res Fdn, New York, NY USA
[3] Sharp Chula Vista Med Ctr, Chula Vista, CA USA
[4] Lilly Res Labs, Indianapolis, IN USA
[5] Mid Carolina Cardiol, Charlotte, NC USA
[6] Hosp Gen Gregorio Maranon, Madrid, Spain
[7] Duke Clin Res Inst, Durham, NC USA
[8] Virginia Beach Gen Hosp, Virginia Beach, VA USA
[9] Moses Cone Mem Hosp, Greensboro, NC USA
[10] Ctr Cardiac & Vasc Res, Takoma Pk, MD USA
[11] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[12] William Beaumont Hosp, Royal Oak, MI 48072 USA
关键词
D O I
10.1016/j.amjcard.2005.04.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombocytopenia. that develops after percutaneous coronary intervention (PCI) may result in hemorrhagic complications, requirement for. blood product transfusions, and potentially thrombotic or ischemic complications. The incidence and prognostic significance of thrombocytopenia, in patients with acute myocardial infarction (AMI) who undergo primary PCI have not been evaluated. In the CADILLAC trial 2,082 patients who had AMI within 12 hours of onset without shock were prospectively randomized to receive balloon angioplasty with or without abciximab versus stenting with or without abciximab. Acquired thrombocytopenia, defined as a nadir platelet count < 100 X 10(9)/L in patients who did not have baseline thrombocytopenia, developed in 50 of 1,975 qualifying patients (2.5%) after primary PCI. By multivariate analysis, acquired thrombocytopenia developed mode frequently in patients who had non-insulin-requiring diabetes mellitus (odds ratio 3.88 [OR], p = 0.0002), previous statin administration (OR 3.28, p = 0.002), and use of abciximab (OR 2.06, p = 0.02) and less frequently in patients, who had previous aspirin use (OR 0726, p = 0.002), a higher baseline platelet count (OR 1.20, p < 0.0001), and greater body mass index (OR 0.90, p = 0.006). Patients who developed thrombocytopenia versus those who did not had higher in-hospital rates of major hemorrhagic complications (10.0% vs 2.7%, p = 0.01), greater requirement for blood transfusions (10.0% vs 3.9%, p = .0.05), longer hospital stay (median 4.8 vs 3.6 days, p = 0.008), and increased costs (median $14,466 vs $11,629, p = 0.001). All-cause mortality was markedly increased at 30 days (8.0%, vs 1.6%, p = 0.0008) and at 1 year (10.0% vs 3.9%, p = 0.03) in patients who developed thrombocytopenia. In conclusion, thrombocytopehia that develops after primary PCI for AMI, although uncommon, is associated with increased hemorrhagic complications and decreased survival. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 20 条
[1]   HEPARIN-ASSOCIATED THROMBOCYTOPENIA - A COMPARISON OF 3 HEPARIN PREPARATIONS [J].
BELL, WR ;
ROYALL, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (16) :902-907
[2]  
Berkowitz S. D., 1997, Blood, V90, p81B
[3]   Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization [J].
Berkowitz, SD ;
Sane, DC ;
Sigmon, KN ;
Shavender, JH ;
Harrington, RA ;
Tcheng, JE ;
Topol, EJ ;
Califf, RM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (02) :311-319
[4]  
BERKOWITZ SD, 1997, THROMB HAEMOSTASIS, V236, pPS962
[5]   HEMORRHAGIC EVENTS DURING THERAPY WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, HEPARIN, AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI), PHASE-II TRIAL [J].
BOVILL, EG ;
TERRIN, ML ;
STUMP, DC ;
BERKE, AD ;
FREDERICK, M ;
COLLEN, D ;
FEIT, F ;
GORE, JM ;
HILLIS, LD ;
LAMBREW, CT ;
LEIBOFF, R ;
MANN, KG ;
MARKIS, JE ;
PRATT, CM ;
SHARKEY, SW ;
SOPKO, G ;
TRACY, RP ;
CHESEBRO, JH .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (04) :256-265
[6]  
BRACEY AW, 1994, ARCH PATHOL LAB MED, V118, P411
[7]   Cost-effectiveness of coronary stenting in acute myocardial infarction - Results from the stent primary angioplasty in myocardial infarction (Stent-PAMI) trial [J].
Cohen, DJ ;
Taira, DA ;
Berezin, R ;
Cox, DA ;
Morice, MC ;
Stone, GW ;
Grines, CL .
CIRCULATION, 2001, 104 (25) :3039-3045
[8]   Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis [J].
Dasgupta, H ;
Blankenship, JC ;
Wood, GC ;
Frey, CM ;
Demko, SL ;
Menapace, FJ .
AMERICAN HEART JOURNAL, 2000, 140 (02) :206-211
[9]  
Ficek S J, 1997, J Extra Corpor Technol, V29, P78
[10]   Simvastatin-induced thrombocytopenia [J].
Groneberg, DA ;
Barkhuizen, A ;
Jeha, T .
AMERICAN JOURNAL OF HEMATOLOGY, 2001, 67 (04) :277-277